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Background: Human papillomavirus (HPV) is associated with different malignancies but its role in the pathogenesis
of ovarian cancer is controversial. This study investigated the prevalence, genotyping and physical state of HPV in
ovarian cancer Saudi patients.
Methods: Hundred formalin fixed paraffin embedded (FFPE) ovarian carcinoma tissues and their normal adjacent
tissues (NAT) were included in the study. HPV was detected by nested polymerase chain reaction (PCR) using
degenerated HPVL1 consensus primer pairs MY09/MY11 and GP5+/GP6 + to amplify a broad spectrum of HPV
genotypes in a single reaction. The HPV positive samples were further genotyped using DNA sequencing. The
physical state of the virus was identified using Amplification of Papillomavirus Oncogene Transcripts (APOT) assay in
the samples positive for HPV16 and/or HPV18.
Results: High percentage of HPV (42%) was observed in ovarian carcinoma compared to 8% in the NAT. The
high-risk HPV types 16, 18 and 45 were highly associated with the advanced stages of tumor, while low-risk types 6
and 11 were present in NAT. In malignant tissues, HPV-16 was the most predominant genotype followed by
HPV-18 and −45. The percentage of viral integration into the host genome was significantly high (61.1%) compared
to 38.9% episomal in HPV positive tumors tissues. In HPV18 genotype the percentage of viral integration was 54.5%
compared to 45.5% episomal.
Conclusion: The high risk HPV genotypes in ovarian cancer may indicate its role in ovarian carcinogenesis. The HPV
vaccination is highly recommended to reduce this type of cancer.
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Polymerase chain reactionIntroduction
Human papillomavirus (HPV) belongs to Papillomaviridae
family that consists of small double stranded DNA viruses
associated with cutaneous and mucosal squamous epithe-
lial lesions [1]. HPV infection is detected in cancers of the
female lower genital tract [2,3]. However, its role in the
development of cancers in the upper genital tract, such
as endometrial and ovarian cancer, is less clear [4].
More than 200 genotypes of HPV have been identified
and were subdivided into two groups the oncogenic and
non-oncogenic group [5]. The oncogenic HPV genotypes* Correspondence: mohhafez_2000@yahoo.com
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[6,7]. Of these, type 16 and 18 have been classified as
“high-risk” (HR-HPV) because they are associated with the
malignant progression of cervical tumors and with other
genital and head-neck malignancies [8]. The high-risk
HPV types produced two oncogenes, designed E6 and E7
proteins induce transformation by interference with en-
dogenous cell cycle regulatory proteins, including P53,
retinoblastoma (Rb) and breast cancer type 1 suscepti-
bility protein (BRAC1) [9]. The L1 open reading frame
(ORF) region is the most conserved gene within the
HPV genome, and has been used for identification of
genotyping and new HPV genotypes [10]. The HPV
detection in clinical samples is based on the DNA frag-
ments amplification in the L1 region [11].ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 PCR products were analyzed on a 2% agarose gel
stained with ethidium bromide and visualized by
UV-trans-illumination. Lane M is 50 PCR marker (Promega), Lanes
1, 5 and 8 are weak positive sample, lanes 2, 3, 4, 6 and 7 are
negative samples, from lane 9-12 are positive samples and lane 13 is
positive control.
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malignancy because it is detected in advanced stages
with 5-year survival rate is <40% [12,13]. The etiology of
ovarian cancer remains unclear and may be multifactorial.
Ovarian cancer is either epithelial carcinomas or malig-
nant germ cell tumors [14]. Its incidence rates are the
highest among developed countries, with rates exceeding
9/100,000 women per year. In Saudi Arabia, ovarian can-
cer is the seventh most common malignancy among fe-
males and accounting for 3.1% of all newly diagnosed
cases with median age of 50 years [15]. Epithelial ovarian
cancer accounts for 85-90% of total ovarian tumor [16].
The genetic alterations associated with ovarian carcin-
omas are well known [17,18]. The risk factors that lead to
ovarian carcinomas include positive family history of ovar-
ian, breast or colon cancer; old age; number of ovulations;
endocrine factors; endometriosis; pelvic inflammation; fat
intake [19]. Other environmental factors as HPV infection
are recently under investigations. The participation of
HPV infection could be suspected to be involved in the
development of ovarian cancer [20]. Several studies pro-
vided highly controversial results [21-26].
The integration site of HPV is extensively investigated
in cell lines and clinical samples of HPV related cancers
at various sites of the body. The integration site for HPV
is random throughout the genome but the Integration
mechanisms are not fully understood [27]. Integration of
HPV into host cell genome is found with a high per-
centage in cervical cancer infected with HPV16 and
HPV18 genotypes, and low in the precancerous lesions
and undetected in early HPV-induced lesion [28-30]. In
late stage of cancers, viral integration into host genome
is important in the disease progression. Viral integration
occurs downstream of the early genes E6 and E7 or in
the E1 or E2 region causing gene inactivation [31].
Therefore, the integration of viral genomes may con-
tribute to a large extent to the neoplastic transformation
process and may trigger chromosomal instability. There
are number of methods for the detection of HR-HPV
integrants in human genome such as Amplification of
Papillomavirus Oncogene Transcripts (APOT), Restriction
Site PCR (RS-PCR), Southern blot and Detection of
Integrated Papillomavirus Sequences (DIPS). The APOT
method is able to detect the integration of viral genome in
clinical lesions even in the presence of a large excess of
non-integrated, episomal, form of viral genomes [32]. The
current study aimed to determine the prevalence, genotyp-
ing and physical state of HPV in cancerous and normal
adjacent tissues from ovarian cancer Saudi patients.
Results
Genomic DNA was isolated from 100 FFPE ovarian
carcinoma and their normal adjacent tissues. All sam-
ples were positive for β-globin gene amplification. Theamplified HPV DNA with MY09/MY11 followed by
GP5+/GP6+ were considered HPV positive and were
subjected to DNA sequencing. The negative samples
by nested PCR were subjected to HPV-type specific
PCR to confirm that the samples were negative. Forty
two out of 100 tumor samples and 8 out of 100 NAT
were positive for HPV by nested PCR as shown in
Figure 1.
The patients’ mean age was 50 ± 11 years (range, 25–78
years). The patients’ age distribution was analyzed and the
prevalence of HPV genotypes was detected among them.
There was no significant difference (P > 0.5) observed in
HPV infection among patients with age <45 compared
to >45 years old, in which 15/35 (42.8%) of the patients
with age <45 years old and 27/65 (41.5%) were positive
for HPV. The HPV infection in relation to histological
grade, HPV was detected in 25% (7/28) of cases with
grade I, 50% (21/42) of cases with grade II and 46.7%
(14/30) of cases with grade III.
By using sequencing technique, the most common de-
tected HPV genotype was HPV-16 in 18/42 (42.9%),
followed by HPV-18 in 11/42 (26.2%), finally HPV-45 in
7.1% as in Figures 2A and 2B. The overlapped sequences
was seen in 10/42 (23.8%) cases that indicates the pres-
ences of more than one HPV genotype.
As the sequencing technique failed to identify the spe-
cific mixed HPV genotypes, therefore type specific PCR
assay was used. Mixed infection with HPV-16/18, HPV-
Figure 2 Sequencing data of HPV genotypes (A) A sequence excised from an electropherogram for HPV type 18 (B) Sequence
alignment of HPV type 16, 18 and 45 using Basic Local Alignment Search (BLAST).
Table 1 The prevalence of different human
papillomavirus genotypes in ovarian cancer and its
adjacent normal tissues
HPV infection Ovarian cancer Normal adjacent tumor
Total positive (42/100) 42% (8/100) 8%
HPV-16 (18/42) 42.9% 0 (0%)
HPV-18 (11/42) 26.2% 0 (0%)
HPV-16/18 (7/42) 16.6% 0 (0%)
HPV-45 3/42 (7.1%) 0 (0%)
HPV-16/45 1/42 (2.4%) 0 (0%)
HPV-18/45 1/42 (2.4%) 0 (0%)
HPV-16/18/45 1/42 (2.4%) 0 (%)
HPV-6 0 (0%) 4/8 (50%)
HPV-11 0 (0%) 4/8 (50%)
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7/42 (16.6%), 2.4%, 2.4%, 2.4% respectively as showed in
Table 1. The prevalence of HPV-6 and HPV-11 (low risk
HPV genotypes) were detected only in NAT HPV posi-
tive samples with 50% of both genotypes (Table 1).
The clinical stages were determined according to the
International Federation of Gynecology and Obstetrics
system (FIGO). The ovarian cancer samples were classified
as followed: stage 1-23%, stage II-37%, stage III-29% and
stage IV-11%. HPV was detected in 21.7% (5/23) stage 1,
40.5% (15/37) stage II, 41% (16/39) stage III and 75% (9/
11) stage IV as showed in Figure 3. The presence of HPV
infection was significantly higher in patients with ad-
vanced stages (FIGO stage III and IV) 50% compared to











































Figure 3 The incidence of human papillomavirus in relation to
ovarian cancer stages. *,# and $ indicate significant difference from





































Figure 4 The incidence of human papillo mavirus type 16 in












































Figure 5 The incidence of human papillomavirus type 18 in
relation to ovarian cancer stages. *, # and $ indicate significant
difference from stage I, satge II and stage III, respectively.
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FIGO stages as followed: HPV-16 were (7/37) 18.9%, (9/
39) 23% and (2/11) 18.2% in stage II, III and IV respect-
ively as showed in Figure 4. HPV-18 was 2/23 (8.7%) in
stage I, 3/37 (8.1%) in stage II, 4/39 (10.%) in stage III and
2/11 (18.2%) in stage IV (Figure 5). On the other hand
HPV-45 was observed in 2 cases ofstageI and in one case
with stage II.
The APOT assay is based on the structural differences
among the 3′-ends of viral oncogene transcripts. The in-
tegration of HR-HPV genomes into the host genome re-
sults in both disruption of the E1 or E2 open reading
frames and deletion of viral early-region from the viral
oncogene-encoding sequences. Thirty six HPV-16, HPV-
18 or HPV-16/-18 positive samples with good quality
RNA, were subjected to study the physical states by
APOT assay. The viral genome was found to be inte-
grated in 22/36 (61.1%), whereas the episomal tran-
scripts were found in 38.9%. Out of the 22 cases with
integrated viral genome the episomal form of HPV was
also detected in 5/22 (22.7%). In HPV-18 genotype posi-
tive samples the percentage of viral integration was
54.5% compared to 45.5% episomal. On the other hand
in HPV-16 genotype positive samples the percentage of
viral integration was 65% compared to 35% episomal.
The integrated state of the virus was significantly found
in 90% in advanced stages III and IV compared to 10%
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integrated form was associated with the advanced stages
of cancer.
Discussion
The role of HPV infection in cervical cancer [33] and
other types of cancer [34-37] has been studied. The role of
HPV in ovarian cancer development is debated [24,38-43]
may be due to the different samples size or the technique
used to detect HPV. Therefore, subsequent studies are in
need to confirm the potential impact of HPV in ovarian
cancer. In Saudi Arabia, ovarian cancer represents the sev-
enth most common malignancy and cancer-related deaths
among females [15]. To the best of our knowledge, this is
the first study on the association between HPV infection
and ovarian cancer in Saudi Arabia. This study investi-
gated the presence of HPV genotypes and its physical
states in ovarian cancer Saudi women.
HPVs are classified as high and low risk, according to
their relationship with benign or malignant proliferative
lesions [44]. The oncogenic activity of high-risk HPV
types occurred when they integrated in the host genome.
In many studies, molecular assays were used to identify
different types of HPV in cells and tissues [45-47]. The use
of MY09/MY11 followed by GP5+/GP6+ primers to
enhance the detection sensitivity in samples containing
low viral copy numbers and to amplify a wide spectrum of
HPV genotypes [48]. In the present study, the MY09/
MY11 and GP5+/GP6+ primers followed by DNA sequen-
cing and type specific PCR were used to confirm the HPV
genotypes and to identify the mixed infection. In the
current study, the incidence of HPV was higher in cancer-
ous tissues than in NAT by both the PCR and sequencing
techniques. Some studies detect the high incidence of
high-risk HPV DNA in both benign and ovarian malig-
nant tumors [49,50]. Similar study indicates the import-
ance of HPV in malignant development via the statistical
difference of HPV distribution in benign compared to ma-
lignant ovarian tissue of Chinese patients [4]. In contrast,
other study didn’t find any association between ovarian
cancers and the presence of HPV infection by using PCR
assay [51]. A study in India included 20 ovarian cancer
biopsies, demonstrated complete absence of HPV infec-
tion in ovarian cancer [52]. Other studies have shown
lower rate of HPV DNA in ovarian than cervical cancer
[4,24]. Hence, the identification of HPV DNA in ovarian
tumors may provide an evidence of a metastatic cervical
cancer [53,54]. The geographical variation in HPV variants
showed that the virus and the host has co-evolved over
time [55]. In our study, the identification of high-risk HPV
in cancerous tissues reflects the HPV possible role in ovar-
ian carcinogenesis and the viral type is probably an im-
portant factor. Some host genetic factors is implicated in
HPV persistence such as polymorphism or variation ishuman major histocompatibility class II [56]. Other study
on the cervical cancer Saudi patients found high incidence
of HPV with HPV-16 and −18 the common genotypes.
They concluded that the HPV prevalence in cervical can-
cer patients is comparable to the international rates [8].
In the current study, the high-risk HPV types 16, 18
and 45 were associated with advanced stages of the dis-
ease, while low-risk types 6 and 11 were associated with
normal tissues adjacent to the tumor. This finding was
in agreement with other study found that the presence
of high-risk types of HPV was found in the serous histo-
logical subtype and advanced stages of the disease (FIGO
stages III and IV) [39]. Other studies showed no evi-
dence of high-risk HPV association with histological
subtype and/or stage of disease [4,24]. In ovarian carcin-
oma Serbia patients, HPV infections were more frequent
in FIGO III/IV in relation to FIGO I/II stages [57].
There is no statistical significant difference in HPV
infection in relation to age group more/or less than 45
years. The current study are consistent with those
reports based the detection of HPV in relation to age,
they found that the median age of diagnosis of ovarian
cancer patients infected with HPV was 57 years for
patients with HPV and 59 years for patients without
HPV infection [4].
HR-HPV DNA integration in cervical cancer genome
plays an important role in cancer pathogenesis [1].
HPV-transformed cells growth rate depends on E6 and
E7 oncogenes expression level [58,59], so the integration
is important in HR-HPV-induced cancer. Therefore, the
viral genomes integration resulted in elevated expression
levels of the E6 and E7 oncogenes [60].
Integration of HPV is common in late stage cervical
cancers and considered as an important event in disease
progression. The molecular detection of integrated HR-
HPV genomes may represent a suitable marker for the
identification of invasive carcinoma. Integration gener-
ally occurs in E1 or E2 region downstream of the early
genes E6 and E7. Viral E2 gene is well known to play a
role in viral replication as well as negative regulation of
E6 and E7 genes [39] and transcriptionally inactivated
once the virus gets integrated due to disruption of its
open reading frame. Some studies showed that both
episomal and integrated forms are able to transform
normal keratinocytes [61-63].
The APOT assay allows distinguishing between
integrate- and episome-derived transcripts encompass-
ing HR-HPV E7 sequences. To study the physical state
of HPV, APOT assay was used to detect the integration
of viral genome [32]. In the current study, the percent-
age of viral integration into the host genome was de-
tected in 61.1% of HPV positive tumors and was 38.9%
episomal. The incidence of integration in HPV18 posi-
tive samples was 54.5% compared to 45.% the virus was
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with the advanced stages of cancer. This was inconsist-
ent with other study that was done on the relationship
between integration of HPV and cervical cancer [32].
Similar study found, by applying APOT assay to samples
infected with HR-HPV types 16 and 18, a strong correl-
ation between the detection of integrate-derived tran-
scripts and the progression stage of the cervical dysplasia.
Some investigators detected integrated HPV genomes in
various preneoplastic lesions [64] or in invasive carcinoma
samples [65]. This discrepancy was attributed to the differ-
ent methodological approaches used for the detection of
integrated HPV DNA [65].
Conclusion
This study supports the hypothesis that there was a correl-
ation between HPV infection and ovarian cancer in Saudi
Arabia. The high percentage of HR-HPV associated with
ovarian cancer and its integrated form may reflect a pos-
sible role of this virus in the carcinogenesis of ovarian
tumors or it may facilitate its progression. From this study,
we recommended theadmission of HPV vaccination in the
national vaccination program.
Material and methods
Human papillomavirus and its integration were investi-
gated in ovarian cancer and its normal adjacent tissues
(NAT). The study was conducted in compliance with
Helsinki Declaration and was approved by the review
board of King Khalid Hospital, King Saud University. It
included 100 archival formalin-fixed paraffin embedded
(FFPE) ovarian cancer and their normal adjacent tissues
were collected from Pathology Department, College of
Medicine, King Saud University and Riyadh Regional
Laboratory and blood bank. All the pathological data
were taken from the pathological reports. The mean age
were 50 ±11 years ranging from 25–78 years.
Nucleic acid extraction
Cervical cancers cell lines positive for HPV-16 (SiHa,
CaSki) and HPV-18 (HeLa, C-4 I) were used as positive
control for genotypes and for viral integration. All FFPE
samples were thin sectioned at 8 μm thicknesses using
Leica Microtome (Manual Rotary Microtome RM2235).
Tissue sections were floated in a DEPC-treated water
bath then picked up on glass slides then allowed to dry.
Genomic DNA was used for HPV genotyping and
RNA was used to detect the integration of HPV. Three
tissue sections were used for RNA and DNA extraction
using Recover All total Nucleic Acid Isolation Kit
(Ambion, Life Technologies, USA) following the manu-
facturer instructions. In brief the tissue sections were
deparaffinized then digested by proteases. The nucleic
acid was isolated by preparing the isolation additive/ethanol mixture followed by transfer to the column then
eluted. The quantity and quality of the RNA and DNA
were characterized using a UV spectrophotometer
(NanoDrop8000, Thermo scientific, USA).
Human papillomavirus detection by nested PCR
The specimens were amplified with beta-globin primers
GH20 and GH21 in order to check the DNA quality.
Nested PCR with consensus primers MY09/MY11 was
used to amplify a wide spectrum of HPV types with PCR
product of 450 bp followed by GP5+/GP6+ with PCR
product of approximately 150 bp as previously described
[66]. Each sample was tested three times. The primers
sequences are shown in Table 2. The PCR reaction was
done in 50 μl, contained 500 ng of DNA, 1XPCR Master
Mix (Promega, Madison, USA), 3 mMMgCl2, 300 nM
of each primer. Amplifications using MY09/MY11were
performed with the following cycling profile: incubation
at 94°C for 5 min followed by 40 cycles of 1 min de-
naturation at 95°C, 1 min annealing at 55°C, and 1 min
elongation at 72°C. The last cycle was followed by a
final extension of 10 min at 72°C. The annealing step of
GP5+/GP6+ primers-based PCR was performed at 40°C
for 2 min. During amplification positive and negative
control samples were included. PCR products were ana-
lyzed on a 2% agarose gel stained with ethidium bromide
and visualized by UV-transillumination Figure 1.
Type‐specific PCR
Multiple infections and negative samples were subjected
to type-specific PCR to confirm the results. The amplifi-
cation reactions were performed using 18 HPV primers
as previously described [67] (13 for HR-HPV 16, 18, 31,
33,45, 35, 39, 51, 52, 56, 58, 66, and 68 and 5 for Low
risk HPV 6,11,42,43 and 44) in separate reactions. Each
reaction was performed in a final volume of 50 μL con-
taining 500 ng of DNA, 1 × PCR Buffer 300 nM of each
primer, and 1 U of Taq polymerase (KAPABIOSYSTEM,
USA). The amplification conditions were 95°C for 10
min followed by 40 cycle of 1 min denaturation at 95°C,
1 min annealing temperature vary for each primers, and
2 min extension at 72°C. The last cycle was followed by
a final extension of 10 min at 72°C.
Amplification of papillomavirus oncogene transcripts
(APOT)
cDNA was synthesized from 1 μg of total RNA by re-
verse transcription using an oligo(dT)17-primer coupled
to a linker sequence p3 using a high capacity cDNA
kit (Applied biosystem, life technology, USA), accord-
ing to the manufacturer’s instructions. To control
RNA integrity and cDNA quality, PCR reactions using
glyceraldehyde-3-phosphate dehydrogenase–specific primers
were performed.
Table 2 Primers sequence used in this study
Primers Forward primer Reverse primer
MY09/MY11 5′-CGTCC(AC)A(AG)(AG)GGA(T)ACTGATC-3′ 5′-GC(AC)CAGGG(AT)CATAA(CT)AATGG-3′
GP5+/GP6+ 5′-TTTGTTACTGTGGTAGATACTAC-3′ 5′-GAAAAATAAACTGTAAATCATATTC-3′
HPV-16 5′-CAC AGT TAT GCA CAG AGC TGC-3′ 5′-CAT ATA TTC ATG CAA TGT AGG TGTA-3′
HPV-18 5′-CAC TTC ACT GCA AGA CAT AGA-3′ 5′-GTT GTG AAA TCG TCG TTT TTC A-3′
HPV-31 5′-GAA ATT GCA TGA ACT AAG CTC G-3′ 5′-CAC ATA TAC CTT TGT TTG TCA A-3′
HPV-59 5′-CAA AGG GGA ACT GCA AGA AAG-3′ 5′-TAT AAC AGC GTA TCA GCA GC-3′
HPV-45 5′-GTG GAA AAG TGC ATT ACA GG-3′ 5′-ACC TCT GTG CGT TCC AAT GT-3′
HPV-33 5′-ACT ATA CAC AAC ATT GAA CTA-3′ 5′-GTT TTT ACA CGT CAC AGT GCA-3′
HPV 6/11 5′-TGC AAG AAT GCA CTG ACC AC-3′ 5′-TGC ATG TTG TCC AGC AGT GT-3′
HPV-58 5′-GTA AAG TGT GCT TAC GAT TGC-3′ 5′-GTT GTT ACA GGT TAC ACT TGT-3′
HPV-52 5′-TAA GGC TGC AGT GTG TGC AG-3′ 5′-CTA ATA GTT ATT TCA CTT AAT GGT-3′
HPV-56 5′-GTG TGC AGA GTA TGT TTA TTG-3′ 5′-TTT CTG TCA CAA TGC AAT TGC-3′
HPV-35 5′-CAA CGA GGT AGA AGA AAG CAT C-3′ 5′-CCG ACC TGT CCA CCG TCC ACCG-3′
HPV-42 5′-CCC AAA GTA GTG GTC CCA GTT A-3′ 5′-GAT CTT TCG TAG TGT CGC AGT G-3′
HPV-43 5′-GCA TAA TGT CTG CAC GTA GCT G-3′ 5′-CAT GAA ACT GTA GAC AGG CCA AG-3′
HPV-44 5′-TAA ACA GTT ATA TGT AGT GTA CCG-3′ 5′-TAT CAG CAC GTC CAG AAT TGA C-3′
HPV-68 5′-GCA GAA GGC AAC TAC AAC GG-3′ 5′-GTT TAC TGG TCC AGC AGT GG-3′
HPV-39 5′-GAC GAC CAC TAC AGC AAA CC-3′ 5′-TTA TGA AAT CTT CGT TTG CT-3′
HPV-51 5′-GAG TAT AGA CGT TAT AGC AGG-3′ 5′-TTT CGT TAC GTT GTC GTG TAC G-3′
HPV-66 5′-TTC AGT GTA TGG GGC AAC AT-3′ 5′-AAA CAT GAC CCG GTC CAT GC-3′
GAPDH 5′-CCACTCCTCCACCTTTGA-3′ 5′-ACCCTGTTGCTGTAGCCA-3′
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quently amplified by PCR using HPVE7–specific primer
[P1-16] for HPV16 and [P1-18] for HPV18 as forward
primers and linker p3 as the reverse primer. The PCR
was performed in 50 μL reaction volume containing
5 μL of the RT reaction mixture (cDNA), 2.5 units Taq
polymerase (promega madison wisconsin, USA), 1×
PCR buffer (500 mMKCl, 1.5 mM MgCl2), 200 μM each
of the deoxyribonucleotide triphosphate and 0.25 μM of
each primer. The reaction mixture was subjected to
initial denaturation for 2 min, followed by 35 cycles of
denaturation at 94°C for 45 s, annealing at 58°C for 45 s,
elongation at 72°C for 2 min, and a final elongation step
at 72°C for 7 min. Five μl of the amplified products were
used as template for nested PCR under the same condi-
tions at annealing temperature 65°C using forward
HPVE7-specific primer [p2-16] specific for HPV16 and[P2-18] specific for HPV18 as forward primers and (dT)
17-p3 as reverse primer [64].
DNA sequencing
To identify the HPV genotypes and the integration, all
positive PCR products were analyzed by direct DNA se-
quencing. PCR products were purified using QIAquick
Purification Kit according to manufacturer’s instructions
(QIAGEN, Hilden, Germany). Purified PCR products were
labeled with fluorescent dyes using BigDye Terminator
v3.1 Cycle Sequencing Kit Applied Biosystem. Labeled oli-
gonucleotides were purified using BigDye X Terminator
Purification Kit (Applied Biosystems, CA, USA).
The samples were sequenced by automatic ABI 3500
genetic analyzer (Applied Biosystems, USA). Chromato-
grams with sharp peaks and quality values ≥20 with little
or no background noise consider as single HPV infection.
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direct sequencing gave mixed chromatograms, with over-
lapping peaks or two or more fluorescent signals. Samples
with mixed chromatogram were subsequently subjected to
type-specific PCR. The nucleotide sequences were sub-
sequently subjected to Basic Local Alignment Search
(BLAST) provided by the National Cancer Institute,
USA.
Statistics
Chi-square test used to test prevalence differences in HPV
genotypes and integration frequencies between different
HPV types in cancerous tissues and NAT in relation to
age, tumor stage and tumor grade. A p value of < 0.05 was
considered statistically significant. SPSS, version 17.0 was
used for these analyses.
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